› 4rcp

X-ray diffraction
1.6Å resolution

Crystal structure of Plk1 Polo-box domain in complex with PL-2

Released:
DOI: 10.2210/pdb4rcp/pdb
PDB entry 4rcp coloured by chain, front view.
PDB entry 4rcp coloured by chain, side view.
PDB entry 4rcp coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY, Kim HY, Ryu EK, Murugan RN, Kim NH, Bang JK
J Med Chem 58 294-304 (2015)
PMID: 25347203

Function and Biology Details

Reaction catalysed: 
ATP + a protein = ADP + a phosphoprotein
Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-156776 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Serine/threonine-protein kinase PLK1 Chain: A
Molecule details ›
Chain: A
Length: 228 amino acids
Theoretical weight: 26.37 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: P53350 (Residues: 372-599; Coverage: 38%)
Gene names: PLK, PLK1
Sequence domains: POLO box duplicated region
Structure domains: POLO box domain
PL-2 Chain: B
Molecule details ›
Chain: B
Length: 5 amino acids
Theoretical weight: 636 Da
Source organism: Homo sapiens
Expression system: Not provided

Ligands and Environments

1 bound ligand:
Ligand EDO 10 x EDO
1 modified residue:
Ligand TPO 1 x TPO

Experiments and Validation Details

Entry percentile scores
X-ray source: PHOTON FACTORY BEAMLINE BL-1A
Spacegroup: P21
Unit cell:
a: 39.39Å b: 61.27Å c: 51.26Å
α: 90° β: 103.27° γ: 90°
R-values:
R R work R free
0.189 0.189 0.204
Expression systems:
  • Escherichia coli BL21(DE3)
  • Not provided

Quick links

Citations

4 review citations

Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.
Park et al. (2017)
3 more